trial

Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder

NCTId NCT00373672
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 58 (actual)
Sponsored by Northwestern University
Primary completion 2010-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
58 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2006-08
Primary completion
2010-01
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
armodafinil (Nuvigil)

Sponsors

Northwestern UniversityLead Sponsor
National Alliance for Research on Schizophrenia and DepressionCollaborator
CephalonCollaborator

Investigators

1
William R. McFarlane, M.D.Principal Investigator

Sites

1 total
Nashville, United States

Facts & assertions

4 sourced
Enrollment
58
Phase
PHASE4
Primary Completion Date
2010-01
Status
COMPLETED
relationships
The graph out of here
drug
armodafinil (Nuvigil)
drug
lead_sponsor
Northwestern University
company
collaborator
National Alliance for Research on Schizophrenia and Depression
company
Cephalon
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
William R. McFarlane, M.D.
person